Study: Chinese COVID shot may offer elderly poor protectionhttps://medicalxpress.com/news/2021-07-chinese-covid-shot-elderly-poor.htmlA new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company's shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm's Beijing Institute of Biological Products.
"This is very, very worrying that these people, who are high-risk, have a poor antibody response," said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study.
Sinopharm's vaccine has not been tested in the US, and is not authorized for use in the US. At least some countries where it is being used have experienced surges in new cases of Covid, and this could illuminate that problem. Since Sinovac's vaccine uses the same inactivated virus technology - unlike J&J, Moderna, and Pfizer (or Novavax, which has not yet applied for EUA) - and has seen poor results in some countries using their vaccine, I wonder whether it also has a similar age-related issue with antibody production and concentrations.
